Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects

被引:14
|
作者
Tsukahara, Kengo [1 ]
Kimura, Kazuo [1 ]
Morita, Satoshi [1 ]
Ebina, Toshiaki [1 ]
Kosuge, Masami [1 ]
Hibi, Kiyoshi [1 ]
Iwahashi, Noriaki [1 ]
Endo, Mitsuaki [1 ]
Maejima, Nobuhiko [1 ]
Sugano, Teruyasu [1 ]
Umemura, Satoshi [1 ]
机构
[1] Yokohama City Univ, Med Ctr, Div Cardiol, Minami Ku, Yokohama, Kanagawa 2320024, Japan
关键词
Platelet inhibitors; Drug interactions; Coronary artery disease; PERCUTANEOUS CORONARY INTERVENTION; ELUTING STENT THROMBOSIS; PLATELET REACTIVITY; INCREASED RISK; CLOPIDOGREL RESISTANCE; CARDIOVASCULAR EVENTS; HEALTHY-SUBJECTS; THERAPY; ASPIRIN; RESPONSIVENESS;
D O I
10.1016/j.jjcc.2011.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although there has been an intense debate whether concomitant use of proton-pump inhibitors (PPIs) attenuates the antiplatelet effects of thienopyridine derivatives, the drug drug interaction remains unclear in Japanese patients with coronary artery disease. Methods and results: Platelet function test was performed in 461 patients who were scheduled for or had undergone stent implantation, treated with 100 mg/day of aspirin and a thienopyridine (200 mg/day of ticlopidine or 75 mg/day of clopidogrel) for at least 14 days. Adenosine diphosphate-induced platelet aggregation was evaluated with screen filtration pressure method, and the upper quartile of high platelet reactivity was defined as high on-treatment platelet reactivity (HPR). PPI use was at physician's discretion. Patients taking a thienopyridine plus a PPI (n = 166) were older and had a higher incidence of acute coronary syndromes on admission compared with patients taking a thienopyridine without a PPI (n = 295). The rate of HPR was higher in patients taking a thienopyridine plus a PPI than in patients taking a thienopyridine without a PPI (31% vs 21%, p=0.01). On multivariate logistic regression analysis, independent predictors of HPR were concomitant PPI use [odds ratio (OR): 1:66, 95% confidence interval (CI): 1.03-2.68], diabetes mellitus (OR: 1.76, CI: 1.11-2.81), and calcium channel blockers use (OR: 1.93, CI: 1.18-3.18). However, there was no significant difference in the rate of extremely high platelet reactivity [58 patients (12.5%) with PATI <4.0 mu M] between patients treated with a thienopyridine plus a PPI and those without a PPI (14% vs 11%, NS). Conclusion: HPR was frequently observed in Japanese patients treated with thienopyridines plus PPIs compared to those without PPIs. Further prospective studies are needed to estimate the risk of adverse cardiovascular events associated with concomitant use of PPIs and thienopyridines. (C) 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:275 / 282
页数:8
相关论文
共 50 条
  • [1] Safe use of proton-pump inhibitors
    de Prados, Carlos Martin de Argila
    Cardona, Julia Lopez
    Arias, Federico Argueelles
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2023, 115 (09) : 475 - 479
  • [2] The appropriate use of proton-pump inhibitors
    Savarino, Vincenzo
    Marabotto, Elisa
    Zentilin, Patrizia
    Furnari, Manuele
    Bodini, Giorgia
    De Maria, Costanza
    Pellegatta, Gaia
    Coppo, Claudia
    Savarino, Edoardo
    MINERVA MEDICA, 2018, 109 (05) : 386 - 399
  • [3] Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
    Sibbing, Dirk
    Morath, Tanja
    Stegherr, Julia
    Braun, Siegmund
    Vogt, Wolfgang
    Hadamitzky, Martin
    Schoemig, Albert
    Kastrati, Adnan
    von Beckerath, Nicolas
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (04) : 714 - 719
  • [4] Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes
    Mandurino-Mirizzi, Alessandro
    Leonardi, Sergio
    Meloni, Chiara
    MINERVA ENDOCRINOLOGICA, 2017, 42 (03) : 228 - 237
  • [5] Appropriate Use and Stewardship of Proton-Pump Inhibitors
    Ren, Dylan
    Gurney, Erin
    Hornecker, Jaime R.
    US PHARMACIST, 2019, 44 (12) : 25 - 31
  • [6] Retrospective evaluation of the use of proton pump inhibitors in patients on concomitant anticoagulant and antiplatelet therapy
    Patil, Tanvi
    Murphy, Kimberly
    Woodard, Laura
    Lebrecht, Morgan
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (04) : 616 - 616
  • [7] Sticky Palms Following Use of Proton-Pump Inhibitors
    Alkeraye, Salim
    Baclet, Yves
    Delaporte, Emmanuel
    JAMA DERMATOLOGY, 2016, 152 (06) : 722 - 723
  • [9] A review of proton-pump inhibitors
    Smith, Haley
    SA PHARMACEUTICAL JOURNAL, 2014, 81 (05) : 13 - 16
  • [10] Proton-pump inhibitors and fractures
    Carol Wilson
    Nature Reviews Endocrinology, 2012, 8 (11) : 625 - 625